生物靶向治疗药物在狼疮性肾炎中的研究进展

Research progress in biological targeted therapy drugs for lupus nephritis

狼疮性肾炎(lupus nephritis,LN)是系统性红斑狼疮(systemic lupus erythematosus,SLE)的一种常见且严重的脏器损害,是导致SLE患者死亡的主要原因之一。常规用药疗效有限且不良反应多,现随着对LN分子机制研究的不断深入,针对特异性的致病靶点治疗药物和治疗方法不断涌现,受到临床医生和免疫学者的极大关注。本文基于LN的发病机制,综述LN靶向治疗药物的临床应用和相关临床研究进展,以期为临床医生更精准地诊治SLE与LN、减轻LN肾脏损伤、维持疾病长期缓解提供依据。

Lupus nephritis(LN)is a common and serious organ damage of systemic lupus erythematosus(SLE),and is one of the main causes of death in SLE patients.Conventional medication has limited efficacy and many adverse reactions.With the continuous deepening of research on the molecular mechanism of LN,therapeutic drugs and methods targeting specific pathogenic targets are constantly emerging,attracting great attention from clinical doctors and immunologists.Based on the pathogenesis of LN,this article reviews the clinical application and progress in related clinical research of targeted therapy drugs for LN,in order to provide a basis for clinicians to more accurately diagnose and treat SLE and LN,reduce LN kidney damage,and maintain long-term remission of the disease.